Showing 5431-5440 of 8840 results for "".
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new
- Mark D. Kaufmann, MD, FAAD Takes the Helm at AADhttps://practicaldermatology.com/news/mark-d-kaufmann-md-faad-takes-the-helm-at-aad/2461126/Long-time Practical Dermatology® Digital Practice editor Mark D. Kaufmann, MD, FAAD, is the new President of the American Academy of Dermatology. Dr. Kaufmann, a clinical professor of the Departmen
- Study: Laser Surgery Lawsuits Less Likely with Physician Operatorshttps://practicaldermatology.com/news/study-laser-surgery-lawsuits-less-likely-with-physician-operators/2461113/The majority of liability claims due to a cutaneous laser surgery device between 2012 and 2020 involved a non-physician operator, according to a new study in the March 2022 issue of Dermatologic Surgery. Researchers analyzed cases of liability claims due to a cutaneou
- Almirall and University of Michigan Collaborate to Gain Understanding of Disease Drivers in Hidradenitis Suppurativahttps://practicaldermatology.com/news/almirall-and-university-of-michigan-collaborate-to-gain-understanding-of-disease-drivers-in-hidradenitis-suppurativa/2461107/Almirall, S.A. entered into a collaboration agreement with the University of Michigan to accelerate the understanding of the factors that trigger hidradenitis suppurativa. Through this partnership, Almirall's expertise in skin diseases will be combined with the knowledge of the Dermatolo
- Dermatologists Can Support Medical, Humanitarian Efforts in Ukrainehttps://practicaldermatology.com/news/how-to-help-ukraine/2461103/Many Americans feel hopeless as they watch images of displaced Ukrainian citizens fleeing their country due to ongoing Russian attacks. EADV President Professor Alexander Stratigos and Secretary General Professor Carmen Salavastru have issued a sta
- Differin Doubles Down on Retinoid Education Week with New Campaign Launchhttps://practicaldermatology.com/news/differin-doubles-down-on-retinoid-education-week-with-new-campaign-launch/2461100/Differin Gel is launching a digital and audio marketing campaign that will culminate in a strategic partnership with Acast Creative and the
- P&G Ventures Reintroduces Bodewell Line for Eczema and Psoriasishttps://practicaldermatology.com/news/pg-ventures-reintroduces-bodewell-line-for-eczema-and-psoriasis/2461098/P&G Ventures is reintroducing Bodewell, a line of skin care products for people with eczema and psoriasis. Bodewell’s new eczema and psoriasis lines feature actives like Colloidal Oatmeal and Salicylic Acid along with essential moisturizers and a novel botanical blend ca
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- Positive Interim Data Seen with Sirnaomics Ltd’s STP705 in BCChttps://practicaldermatology.com/news/positive-interim-data-seen-with-sirnaomics-ltds-stp705-in-bcc/2461089/Interim data from a Phase 2 clinical trial of Sirnaomics Ltd’s STP705 shows a dose response with complete response, as well as improved or stable cosmetic result with no significant cutaneous skin reactions among patients with cutaneous basal cell carcinoma (BCC). The new data als